Gene Therapy - technologies, markets and companies by Ubiquick

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Gene Therapy - technologies, markets and companies Published on September 2011

Report Summary Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader. Gene therapy can now combined with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression. Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included. Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of January 2010, over 2024 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide.A breakdown of these trials is shown according to the areas of application. Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including germline gene therapy. The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2010-2020. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets The voluminous literature on gene therapy was reviewed and selected 700 references are appended in the bibliography.The references are constantly updated. The text is supplemented with 72 tables and 13 figures. Profiles of 188 companies involved in developing gene therapy are presented along with 207 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by

Gene Therapy - technologies, markets and companies (From Issuu)

Page 1/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies.

Table of Content TABLE OF CONTENTS 0. Executive Summary 19 1. Introduction 21 Definitions 21 Historical evolution of gene therapy 21 Relation of gene therapy to other biotechnologies 23 Molecular biological basics for gene therapy 23 Genome 23 DNA 24 RNA 24 Alternative RNA splicing 25 Genes 26 Gene regulation 26 Gene expression 28 Chromosomes 28 Telomeres 29 Mitochondrial DNA 29 Proteins 30 2. Gene Therapy Technologies 31 Classification of gene therapy techniques 31 Ex vivo and in vivo gene therapy 32 Ex vivo gene therapy 32 In vivo gene therapy 33 Physical methods of gene transfer 33 Electroporation 33 Applications of electroporation 34 Clinical applications of electroporation 35 Advantages of electroporation 35 Limitations of electroporation 36 Hydrodynamic 36 Microinjection 36 Particle bombardment 37 Ultrasound-mediated transfection 39 Molecular vibration 39 Application of pulsed magnetic field and superparamagnetic nanoparticles 39 Gene transfection using laser irradiation 40 Photochemical transfection 40 Chemical methods of gene transfer 41 Gene repair and replacement 41

Gene Therapy - technologies, markets and companies (From Issuu)

Page 2/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Gene repair by single-stranded oligonucleotides 41 History and current status of chimeraplasty 42 mRNA gene therapy 42 Spliceosome mediated RNA trans-splicing 42 Vectors for gene therapy 43 Basic considerations 43 Use of genes as pharmaceuticals 44 The ideal vector for gene therapy 44 Viral vectors 45 Adenovirus vectors 46 Adeno-associated virus vectors 48 Alphavirus vectors 50 Baculovirus vectors 50 Foamy virus vectors 51 Herpes simplex virus vectors 51 Lentiviral vectors 53 Multicistronic retroviral vectors 54 Retroviral vectors 55 Oncogenic potential of retroviral vectors 56 Future prospects of viral vectors 57 Companies using viral vectors 57 Nonviral vectors for gene therapy 59 Anionic lipid-DNA complexes 59 Cationic lipid-DNA complexes 60 Effects of shape of DNA molecules on delivery with nonviral vectors 60 Electrostatic modifications of surface to improve gene delivery 60 Liposomes for gene therapy 61 Liposome-nucleic acid complexes 62 Liposome-HVJ complex 63 Transposons DNA vectors 63 Polycation-DNA complexes (polyplexes) 64 Plasmid DNA vector for treatment of chronic inflammatory disease 65 Polymer molecules 65 Synthetic biology and DNA vectors 65 Synthetic peptide complexes 66 Future prospects of nonviral vs viral vectors 66 Nanobiotechnology for gene therapy 66 Antisense nanoparticles for gene regulation 67 Biological nanoparticle technology 67 Dendrimers 67 Cochleates 67 Calcium phosphate nanoparticles as nonviral vectors 68 Gelatin nanoparticles for gene delivery 68 Lipid nanoparticles for nucleic acid delivery 69 Nanoparticles as nonviral vectors for gene therapy 69 Nanoparticles with virus-like function as gene therapy vectors 70 Nanobiolistics for nucleic acid delivery 70 Nonionic polymeric micelles for oral gene delivery 70

Gene Therapy - technologies, markets and companies (From Issuu)

Page 3/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Silica nanoparticles as a nonviral vector for gene delivery 71 Receptor-mediated endocytosis 71 Artificial viral vectors 72 Directed evolution of AAV to create efficient gene delivery vectors 73 Bacterial ghosts as DNA delivery systems 73 Bacteria plus nanoparticles for gene delivery into cells 73 Chromosome-based vectors for gene therapy 75 Mammalian artificial chromosomes (MACs) 76 Artificial Chromosome Expression (ACE) 76 Human artificial chromosomes (HACs) 76 'C31 integrase system 77 Companies using nonviral vectors 77 Concluding remarks about vectors 78 Cell-mediated gene therapy 79 Fibroblasts 79 Skeletal muscle cells 80 Vascular smooth muscle cells 81 Keratinocytes 81 Hepatocytes 81 Lymphocytes 82 Regulating protein delivery by genetically encoded lymphocytes 82 Implantation of microencapulated genetically modified cells 82 Stem cell gene therapy 83 Therapeutic applications for hematopoietic stem cell gene transfer 83 Improving delivery of genes to stem cells 83 Lentiviral vectors for gene transfer to marrow stem cells 84 Use of mesenchymal stem cells for gene therapy 84 Microporation for transfection of MSCs 84 In utero gene therapy using stem cells 84 Gene delivery to stem cells by artificial chromosome expression 85 Linker based sperm-mediated gene transfer technology 85 Combination of gene therapy with therapeutic cloning 85 Expansion of transduced HSCs in vivo 86 The future of hematopoietic stem cell gene therapy 86 Routes of administration for gene therapy 86 Direct injection of naked DNA 87 Intramuscular injection 87 Intravenous DNA injection 87 Intraarterial delivery 87 Companies with gene delivery devices/ technologies 88 Targeted gene therapy 89 Targeted integration 89 Bacteriophage integrase system for site-specific gene delivery 90 Controlled-release delivery of DNA 90 Controlled gene therapy 91 Controlled delivery of genetic material 91 Controlled induction of gene expression 91 Drug-inducible systems for control of gene expression 92

Gene Therapy - technologies, markets and companies (From Issuu)

Page 4/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Timed activation of gene therapy by a circuit based on signaling network 92 Small molecules for post-transcriptional regulation of gene expression 92 Engineered zinc finger DNA binding proteins for gene correction 93 Light Activated Gene Therapy 93 Spatial control of gene expression via local hyperthermia 93 Companies with regulated /targeted gene therapy 94 Gene marking 95 Germline gene therapy 95 Potential applications of human germline genome modification 95 Pros and cons of human germline genome modification 96 Role of gene transfer in antibody therapy 97 Genetically engineered vaccines 97 DNA vaccines 98 DNA inoculation technology 98 Methods for enhancing the potency of DNA vaccines 99 Advantages of DNA vaccines 99 Vaccine vectors 99 Challenges and limitations of genetically engineered vaccines 100 Vaccines based on reverse genetics 101 Technologies for gene suppression 101 Antisense oligonucleotides 101 Transcription factor decoys 102 Aptamers 103 Ribozymes 103 Peptide nucleic acid 103 Intracellular delivery of PNAs 103 Locked nucleic acid 104 Zorro-LNA 104 Gene silencing 104 Post-transcriptional gene silencing 105 Definitions and terminology of RNAi 105 RNAi mechanisms 105 Inhibition of gene expression by antigene RNA 106 RNAi gene therapy 107 microRNA gene therapy 107 Application of molecular diagnostic methods in gene therapy 107 Use of PCR to study biodistribution of gene therapy vector 108 PCR for verification of the transcription of DNA 108 In situ PCR for direct quantification of gene transfer into cells 108 Detection of retroviruses by reverse transcriptase (RT)-PCR 109 Confirmation of viral vector integration 109 Monitoring of gene expression 109 Monitoring of gene expression by green fluorescent protein 109 Monitoring in vivo gene expression by molecular imaging 110 Advantages of gene therapy compared with protein therapy 110 3. Clinical Applications of Gene Therapy 111 Introduction 111 Bone and joint disorders 111

Gene Therapy - technologies, markets and companies (From Issuu)

Page 5/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Bone fractures 111 Gene therapy for intervertebral disc degeneration 112 Spinal fusion 112 Osteogenesis imperfecta 113 Rheumatoid arthritis 113 Local or systemic treatment 114 In vivo or ex vivo gene therapy of RA 114 Clinical trials 115 Gene therapy for osteoarthritis 116 Sports injuries 117 Repair of articular cartilage defects 117 Regeneration and replacement of bone by gene therapy 118 Bacterial infections 119 Antisense approach to bacterial infections 119 Dentistry 119 Tissue engineering in dental implant defects 119 Endocrine and metabolic disorders 120 Introduction 120 Gene therapy of obesity 120 Ad viral vector-mediated transfer of leptin gene 120 AAV vector-mediated delivery of GDNF for obesity 121 Diabetes mellitus 121 Methods of gene therapy of diabetes mellitus 121 Viral vector-mediated gene transfer in diabetes 122 Gene delivery with ultrasonic microbubble destruction technology 123 Genetically engineered cells for diabetes mellitus 123 Genetically altered liver cells 123 Genetically modified stem cells 124 Genetically engineered dendritic cells 124 Insertion of gene encoding for IL-4 124 Leptin gene therapy 125 Concluding remarks about cell and gene therapy of diabetes 125 Gene therapy of growth-hormone deficiency 125 Gastrointestinal disorders 126 Introduction 126 Methods of gene transfer to the gastrointestinal tract 127 Direct delivery of genes 127 Naked plasmid DNA into the submucosa 127 Viral vectors 127 Receptor-mediated endocytosis 127 Indications for gastrointestinal gene therapy 128 Gene therapy for inflammatory disorders of the bowel 128 Gene transfer to the salivary glands 129 Potential clinical applications of salivary gene therapy 129 Hematology 130 Hemophilias 130 Gene therapy of hemophilia 131 Hemophilia A 131

Gene Therapy - technologies, markets and companies (From Issuu)

Page 6/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Hemophilia B 132 Concluding remarks about gene therapy of hemophilias 133 Hemoglobinopathies 133 Stem cell-based gene therapy and RNAi for sickle cell disease 133 Gene therapy for '-thalassemia 134 Gene therapy of Fanconi's anemia 135 Acquired hematopoietic disorders 136 Chronic acquired anemias 136 Neutropenia 137 Thrombocytopenia 137 Concluding remarks about gene therapy of hemoglobinopathies 138 Companies involved in gene thery of hematological disorders 139 In utero/fetal gene therapy 139 Fetal gene transfer techniques 139 Animal models of fetal gene therapy 140 Potential applications of fetal gene therapy 140 Fetal gene therapy for cystic fibrosis 141 Fetal intestinal gene therapy 141 Hearing disorders 141 Potential of gene therapy 142 Vectors for gene therapy of hearing disorders 142 Auditory hair cell replacement and hearing improvement by gene therapy 143 Kidney diseases 143 End-stage renal disease 143 Methods of gene delivery to the kidney 144 Gene transfer into kidney by adenoviral vectors 144 Non-viral gene transfer to the kidneys 144 Gene transfer into the glomerulus by HVJ-liposome 145 Bone marrow stem cells for renal disease 145 Mesangial cell therapy 145 Liposome-mediated gene transfer into the tubules 146 Gene transfer to tubules with cationic polymer polyethylenimine 146 Gene therapy in animal experimental models of renal disease 146 Genetic manipulations of the embryonic kidney 147 Antisense intervention in glomerulonephritis 147 Gene therapy for renal fibrosis 147 Use of genetically engineered cells for uremia due to renal failure 148 Concluding remarks 148 Liver disorders 148 Techniques of gene delivery to liver 149 Direct injection of DNA into liver 149 Local gene delivery by isolated organ perfusion 150 Liposome-mediated direct gene transfer 150 Retroviral vector for gene transfer to liver 150 Adenoviral vectors for gene transfer to liver 150 Receptor-mediated approach 151 Cell therapy for liver disorders 151 Transplantation of genetically modified hepatocytes 151

Gene Therapy - technologies, markets and companies (From Issuu)

Page 7/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Genetically modified hematopoietic stem cells 152 Gene therapy by ex vivo transduced liver progenitor cells 152 Gene therapy of genetic diseases affecting the liver 152 Crigler-Najjar syndrome 152 Hereditary tyrosinemia type I (HT1) 153 Hereditary tyrosinemia type 3 153 Gene therapy of acquired diseases affecting the liver 153 Cirrhosis of liver 153 Ophthalmic disorders 154 Introduction to gene therapy of ophthalmic disorders 154 Degenerative retinal disorders 155 Age-related macular degeneration 155 Inherited retinal degenerations 156 Inherited disorders affecting vision 157 Gene therapy for color blindness 157 Leber congenital amaurosis 157 Retinitis pigmentosa 158 Stargardt disease 159 Usher syndrome 159 X-linked juvenile retinoschisis 160 Proliferative retinopathies 160 Methods of gene transfer to retinal cells 160 DNA nanoparticles for nonviral gene transfer to the eye 161 Prevention of complications associated with eye surgery 162 Prevention of proliferative retinopathy by gene therapy 162 DNA nanoparticles for gene therapy of retinal degenerative disorders 162 Posterior capsule opacification after cataract surgery 162 Autoimmune uveitis 162 Retinal ischemic injury 163 Corneal disorders 163 Glaucoma 164 Disorders of hearing 164 Gene therapy for hearing loss 164 Organ transplantation 165 Introduction 165 DNA vaccines for transplantation 165 Gene therapy for prolonging allograft survival 165 Gene therapy in lung transplantation 166 Role of gene therapy in liver transplantation 166 Gene therapy in kidney transplantation 166 Veto cells and transplant tolerance 167 Pulmonary disorders 167 Techniques of gene delivery to the lungs 168 Adenoviral vectors 168 Non-viral vectors 169 Aerosolization as an aid to gene transfer to lungs. 169 Cystic fibrosis 170 Genetics and clinical features 170

Gene Therapy - technologies, markets and companies (From Issuu)

Page 8/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Gene therapy for CF 170 CFTR gene transfer in CF 170 Concluding remarks about gene therapy of CF 172 Miscellaneous pulmonary disorders 172 Gene therapy for pulmonary arterial hypertension 172 Gene therapy for bleomycin-induced pulmonary fibrosis 173 Pulmonary complications of a1-antitrypsin deficiency 173 Gene therapy for asthma 174 Gene therapy for adult respiratory distress syndrome 175 Gene therapy for lung injury 175 Gene therapy for bronchopulmonary dysplasia 175 Concluding remarks about gene therapy of lungs 176 Companies involved in pulmonary gene therapy 176 Skin and soft tissue disorders 177 Gene transfer to the skin 177 Electroporation for transdermal delivery of plasmid DNA 177 Electroporation for transdermal delivery of DNA vaccines 178 Liposomes for transdermal gene delivery 178 Ultrasound and topical gene therapy 178 Gene therapy in skin disorders 178 Gene therapy of hair loss 179 Gene therapy for xeroderma pigmentosa 179 Gene therapy for lamellar ichthyosis 179 Gene therapy for epidermolysis bullosa 180 Gene transfer techniques for wound healing 180 Urogenital disorders 181 Gene therapy for urinary tract dysfunction 181 Gene therapy for erectile dysfunction 181 NOS gene transfer for erectile dysfunction 181 Clinical trial of hMaxi-K Gene transfer in erectile dysfunction 182 Gene therapy for erectile dysfunction due to nerve injury 182 Concluding remarks on gene therapy for erectile dysfunction 182 Veterinary gene therapy 183 Gene therapy for mucopolysaccharidosis VII in dogs 183 Gene therapy to increase disease resistance 183 Gene therapy for infections 184 Gene therapy for chronic anemia 184 Gene therapy for endocrine disorders 185 Gene therapy for arthritis 185 Cancer gene therapy 185 Brain tumors in cats and dogs 185 Breast cancer in dogs 186 Canine hemangiosarcoma 187 Canine melanoma 187 Canine soft tissue sarcoma 187 Melanoma in horses 188 4. Gene Therapy of Genetic Disorders 189 Introduction 189

Gene Therapy - technologies, markets and companies (From Issuu)

Page 9/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Primary immunodeficiency disorders 190 Severe combined immune deficiency 191 Chronic granulomatous disease 193 Wiskott-Aldrich syndrome 193 Purine nucleoside phosphorylase deficiency 194 Major histocompatibility class II deficiency 194 Future prospects of gene therapy of inherited immunodeficiencies 195 Metabolic disorders 195 Adrenoleukodystrophy 196 Canavan disease 196 Lesch-Nyhan syndrome 197 LPL deficiency 197 Ornithine transcarbamylase deficiency 198 Phenylketonuria 198 Porphyrias 199 Tetrahydrobiopterin deficiency 199 Lysosomal storage disorders. 200 Batten disease 201 Fabry's disease 201 Farber's disease 202 Gaucher disease 202 Animals models of Gaucher's disease 202 Gene therapy of Gaucher's disease 203 Hunter syndrome 204 Combination of cell and gene therapy for Krabbe's disease 204 Metachromatic leukodystrophy 205 Mucopolysaccharidosis type 1 (Hurler syndrome) 205 Niemann-Pick type A disease 206 Pompe disease 206 Sanfilippo A syndrome 207 Sly syndrome 207 Tay-Sachs disease 207 Future prospects of gene therapy of lysosomal storage disorders 208 Trinucleotide repeat disorders 208 Muscular dystrophies 208 Duchenne muscular dystrophy (DMD) 208 Animal models for gene therapy of DMD 209 Antisense approach to DMD 209 Exon-skipping technology for DMD 210 Liposome-mediated gene transfer 210 Myoblast-based gene transfer in DMD 211 Plasmid-mediated gene therapy 211 Post-transcriptional modulation of gene expression in DMD 211 Repair of dystrophin gene 212 Routes of administration of gene therapy in DMD 212 Types of dystrophin constructs 212 Viral vectors for DMD 213 Conclusions and future prospects of gene therapy of DMD 214

Gene Therapy - technologies, markets and companies (From Issuu)

Page 10/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Limb-girdle muscular dystrophy 215 Myotonic dystrophy 215 Spinal muscular atrophy 216 Antisense gene therapy of SMA 216 Hereditary neuropathies 216 Charcot-Marie-Tooth disease 216 Hereditary axonal neuropathies of the peripheral nerves 217 Gene therapy of mitochondrial disorders 217 Companies involved in gene therapy of genetic disorders 218 5. Gene Therapy of Cancer 219 Strategies for cancer gene therapy 219 Direct gene delivery to the tumor 220 Injection into tumor 220 Direct injection of adenoviral vectors 220 Direct injection of a plasmid DNA-liposome complex 221 A polymer approach to local gene therapy for cancer 221 Electroporation for cancer gene therapy 221 Control of gene expression in tumor by local heat 222 Radiation-guided gene therapy of cancer 222 Radioprotective gene therapy 223 Nanoparticles to facilitate combination of hyperthermia and gene therapy 223 Cell-based cancer gene therapy 223 Adoptive cell therapy 224 Cytokine gene therapy 224 Genetic modification of human hematopoietic stem cells 227 Immunogene therapy 227 Cancer vaccines 228 Genetically modified cancer cell vaccines 228 GVAX cancer vaccines 228 Genetically modified dendritic cells 229 Nucleic acid-based cancer vaccines 230 DNA cancer vaccines 230 RNA vaccines 230 Viral vector-based cancer vaccines 230 Intradermal delivery of cancer vaccines by Ad vectors 231 Future prospects of cancer vaccines 231 Companies involved in nucleic acid-based cancer vaccines 231 Monoclonal antibody gene transfer for cancer 232 Transfer and expression of intracellular adhesion-1 molecules 233 Other gene-based techniques of immunotherapy of cancer 233 Fas (Apo-1) 233 Chemokines 233 Major Histocompatibility Complex (MHC) Class I 234 IGF (Insulin-Like Growth Factor) 234 Inhibition of immunosuppressive function in cancer 234 Delivery of toxic genes to tumor cells for eradication 235 Gene-directed enzyme prodrug therapy 235 Combination of gene therapy with radiotherapy 235

Gene Therapy - technologies, markets and companies (From Issuu)

Page 11/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Correction of genetic defects in cancer cells 236 Targeted gene therapy for cancer 236 Antiangiogenic therapy for cancer 236 Bacteria as novel anticancer gene vectors 237 Cancer-specific gene expression 238 Cancer-specific transcription 238 Delivery of retroviral particles hitchhiking on T cells 238 Electrogene and electrochemotherapy 239 Epidermal growth factor-mediated DNA delivery 239 Gene-based targeted drug delivery to tumors 239 Gene expression in hypoxic tumor cells 240 Genetically modified T cells for targeting tumors 240 Genetically engineered stem cells for targeting tumors 241 Hematopoietic stem cells for targeted cancer gene therapy 242 Immunolipoplex for delivery of p53 gene 243 Nanomagnets for targeted cell-based cancer gene therapy 243 Nanoparticles for targeted site-specific delivery of anticancer genes 243 Targeted cancer therapy using a dendrimer-based synthetic vector 244 Tumor-targeted gene therapy by receptor-mediated endocytosis 244 Virus-mediated oncolysis 244 Cancer terminator virus 244 Cytokine-induced killer cells for delivery of an oncolytic virus 245 Monitoring of viral-mediated oncolysis by PET 246 Oncolytic HSV 246 Oncolytic adenoviruses 246 Oncolytic vesicular stomatitis virus 248 Oncolytic paramyxovirus 248 Oncolytic vaccinia virus 248 Targeted cancer treatments based on oncolytic viruses 248 Concluding remarks on oncolytic gene therapy 249 Companies developing oncolytic viruses 249 Apoptotic approach to improve cancer gene therapy 250 Tumor suppressor gene therapy 250 P53 gene therapy 250 BRIT1 gene therapy 251 Nitric oxide-based cancer gene therapy 251 Nitric oxide synthase II DNA injection 251 Gene therapy for radiosensitization of cancer 251 Gene therapy of cancer of selected organs 252 Gene therapy for bladder cancer 252 Gene therapy for glioblastoma multiforme. 252 Adenoviral vectors for treatment of brain tumors 254 Antiangiogenic gene therapy 254 Autophagy induced by conditionally replicating adenoviruses 255 Baculovirus vector for diphtheria toxin gene therapy 255 Cerepro速 (sitimagene ceradenovec) 255 Gene therapy targeting hepatocyte growth factor 256 Genetically engineered MSCs for gene delivery to intracranial gliomas 256

Gene Therapy - technologies, markets and companies (From Issuu)

Page 12/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Intravenous gene delivery with nanoparticles into brain tumors 256 Ligand-directed delivery of dsRNA molecules targeted to EGFR 256 RNAi gene therapy of brain cancer 257 Targeting normal brain cells with an AAV vector encoding interferon-' 257 Viral oncolysis of brain tumors 258 Gene therapy for breast cancer 258 Gene vaccine for breast cancer 259 Recombinant adenoviral ErbB-2/neu vaccine 259 Gene Therapy for ovarian cancer 260 Gene therapy for malignant melanoma 261 Gene therapy of lung cancer 263 Intravenous nanoparticle formulation for delivery of FUS1 gene 263 Aerosol gene delivery for lung cancer 263 Gene therapy for cancer of prostate 264 Experimental studies 264 Nanoparticle-based gene therapy for prostate cancer 264 Tumor suppressor gene therapy in prostate cancer 264 Vaccines for prostate cancer 265 Clinical trials 265 Gene therapy of head and neck cancer 266 Adenoviral vector based P53 gene therapy 266 Gene therapy of pancreatic cancer 266 Rexin-G' for targeted gene delivery in cancer 267 Targeted Expression of BikDD gene 267 Concluding remarks on gene therapy of pancreatic cancer 267 Cancer gene therapy companies 267 6. Gene Therapy of Neurological Disorders 271 Indications 271 Gene transfer techniques for the nervous system 272 Methods of gene transfer to the nervous system 272 Ideal vector for gene therapy of neurological disorders 272 Promoters of gene transfer 272 Lentivirus-mediated gene transfer to the CNS 273 AAV vector mediated gene therapy for neurogenetic disorders 273 Gene transfer to the CNS using recombinant SV40-derived vectors 274 Routes of delivery of genes to the CNS 274 Direct injection into CNS 274 Introduction of the genes into cerebral circulation 275 Introduction of genes into cerebrospinal fluid 275 Intravenous administration of vectors 275 Delivery of gene therapy to the peripheral nervous system 276 Cell-mediated gene therapy of neurological disorders 276 Neuronal cells 276 Neural stem cells and progenitor cells 276 Astrocytes 277 Cerebral endothelial cells 277 Implantation of genetically modified encapsulated cells into the brain 277 Gene therapy of neurodegenerative disorders 277

Gene Therapy - technologies, markets and companies (From Issuu)

Page 13/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Gene therapy for Parkinson disease 277 Rationale 278 Techniques of gene therapy for PD 279 Delivery of neurotrophic factors by gene therapy 282 Delivery of parkin gene 283 Introduction of functional genes into the brain of patients with PD 283 Nanoparticle-based gene therapy for PD 283 Mitochondrial gene therapy for PD 283 RNAi approach to PD 284 Prospects of gene therapy for PD 284 Companies developing gene therapy for PD 285 Gene therapy for Alzheimer disease 286 Rationale 286 NGF gene therapy for AD 286 Neprilysin gene therapy 287 Targeting plasminogen activator inhibitor type-1 gene 288 Gene vaccination 288 Combination of gene therapy with other treatments for AD 288 Gene therapy of Huntington disease 289 Encapsulated genetically engineered cellular implants 289 Viral vector mediated administration of neurotrophic factors 289 RNAi gene therapy 289 Gene therapy of amyotrophic lateral sclerosis 290 Rationale 290 Technique of gene therapy of ALS 290 Gene therapy of cerebrovascular diseases 291 Preclinical research in gene therapy for cerebrovascular disease 291 Animal models of stroke relevant to gene therapy 291 Transgenic mice as models for stroke 292 Animal models for gene therapy of arteriovenous malformations 292 Gene transfer to cerebral blood vessels 292 Gene therapy for vasospasm following subarachnoid hemorrhage 293 NOS gene therapy for cerebral vasospasm 294 Gene therapy for stroke 295 Gene therapy for stroke using neurotrophic factors 296 Gene therapy of strokes with a genetic component 296 Gene therapy for intracranial aneurysms 296 Concluding remarks about gene therapy for stroke 296 Gene therapy of injuries to the nervous system 297 Traumatic brain injury 297 Spinal cord injury 297 Gene therapy of epilepsy 298 Gene therapy for control of seizures 299 Gene therapy for neuroprotection in epilepsy 300 Gene therapy for genetic forms of epilepsy 300 Gene therapy for multiple sclerosis 301 Gene therapy for relief of pain 301 Rationale of gene therapy for pain 301

Gene Therapy - technologies, markets and companies (From Issuu)

Page 14/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Vectors for gene therapy of pain 302 Methods of gene delivery for pain 302 Endogenous analgesic production for cranial neuralgias 303 Gene delivery by intrathecal route 303 Gene transfer for delivery of analgesics to the spinal nerve roots 303 Gene therapy of peripheral neuropathic pain 304 Gene transfer by injections into the brain substance 305 Targets for gene therapy of pain 305 Zinc finger DNA-binding protein therapeutic for chronic pain 305 Gene therapy for producing enkephalin to block pain signals 305 Targeting nuclear factor-'B 306 Gene therapy targeted to neuroimmune component of chronic pain 306 Potential applications of gene therapy for management of pain 306 Concluding remarks on gene therapy for pain 307 Gene therapy for psychiatric disorders 308 Gene therapy for depression 308 Gene therapy for enhancing cognition after stress 309 Gene therapy against fear disorders 309 Companies involved in gene therapy of neurological disorders 309 7. Gene Therapy of Cardiovascular Disorders 311 Introduction 311 Techniques of gene transfer to the cardiovascular system 311 Direct plasmid injection into the myocardium 312 Catheter-based systems for vector delivery 312 Ultrasound microbubbles for cardiovascular gene delivery 313 Vectors for cardiovascular gene therapy 313 Adenoviral vectors for cardiovascular diseases 313 Plasmid DNA-based delivery in cardiovascular disorders 313 Intravenous rAAV vectors for targeted delivery to the heart 314 Hypoxia-regulated gene therapy for myocardial ischemia 314 Angiogenesis and gene therapy of ischemic disorders 314 Therapeutic angiogenesis vs vascular growth factor therapy 315 Gene painting for delivery of targeted gene therapy to the heart 315 Gene delivery to vascular endothelium 316 Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles 316 Vascular stents for gene delivery 316 Gene therapy for genetic cardiovascular disorders 317 Genetic disorders predisposing to atherosclerosis 317 Familial hypercholesterolemia (FH) 317 Apolipoprotein E (apoE) deficiency 319 Hypertension 319 Genetic factors for myocardial infarction 320 Acquired cardiovascular diseases 320 Coronary artery disease with angina pectoris 320 Ad5FGF-4 320 Ischemic heart disease with myocardial infarction 321 Myocardial repair with IGF-1 therapy 322 Metalloproteinase-2 inhibitor gene therapy 323

Gene Therapy - technologies, markets and companies (From Issuu)

Page 15/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! miRNA gene therapy for ischemic heart disease 323 Congestive heart failure 323 Rationale of gene therapy in CHF 323 '-ARKct gene therapy 324 Intracoronary adenovirus-mediated gene therapy for CHF 324 AAV-mediated gene transfer for CHF 325 AngioCell gene therapy for CHF 325 nNOS gene transfer in CHF 326 Cardiomyopathies 326 Cardiac conduction disturbances 326 Gene transfer approaches for biological pacemakers 326 Genetically engineered biological pacemakers 327 Gene therapy and heart transplantation 327 Peripheral arterial disease 328 Incidence and clinical features 328 Current management 328 Gene therapy for peripheral arterial disease 329 Angiogenesis by gene therapy 329 HIF-1' gene therapy for peripheral arterial disease 329 HGF gene therapy for peripheral arterial disease 330 Ischemic neuropathy secondary to peripheral arterial disease 330 Prevention of restenosis after angioplasty 330 Antisense approaches 330 Gene therapy to prevent restenosis after angioplasty 331 Techniques of gene therapy for restenosis 332 NOS gene therapy for restenosis 333 hTIMP-1 gene therapy to prevent intimal hyperplasia 333 Maintaining vascular patency after surgery 334 Companies involved in gene therapy of cardiovascular diseases 334 Future prospects of gene therapy of cardiovascular disorders 335 8. Gene therapy of viral infections 337 Introduction 337 Acquired Immunodeficiency Syndrome (AIDS) 337 Current management of AIDS 337 Gene therapy strategies in HIV/AIDS 338 HIV/AIDS vaccines 338 Insertion of protective genes into target cells. 339 Cell/gene therapies for HIV/AIDS 340 Transplantation of genetically modified T-cells 340 Transplantation of genetically modified hematopoietic cells 340 Anti-HIV ribozyme delivered in hematopoietic progenitor cells 341 Inhibition of HIV-1 replication by lentiviral vectors 341 VRX496 341 Intracellular immunization 342 Engineered cellular proteins such as soluble CD4s 342 Intracellular antibodies 342 Anti-rev single chain antibody fragment 342 Use of genes to chemosensitize HIV-1 infected cells 343

Gene Therapy - technologies, markets and companies (From Issuu)

Page 16/19

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Autocrine interferon (INF)-' production by somatic cell gene therapy 343 Antisense approaches to AIDS 343 RNA decoys 343 Antisense oligodeoxynucleotides 343 RNA decoys 344 Ribozymes 344 RNAi applications in HIV/AIDS 345 siRNA-directed inhibition of HIV-1 infection 345 Role of the nef gene during HIV-1 infection and RNAi 345 Bispecific siRNA constructs 346 Targeting CXCR4 with siRNAs 346 Targeting CCR5 with siRNAs 346 Companies involved in developing gene therapy for HIV/AIDS 347 Conclusions regarding gene therapy of HIV/AIDS 348 Genetic vaccines for other viral infections 348 Cytomegalic virus infections 348 Viral hepatitis 349 Vaccine for hepatitis B virus 349 Vaccine for hepatitis C virus 350 Vaccine for herpes simplex virus 350 DNA vaccine against rabies 350 DNA vaccine for Ebola 351 Vaccines for avian influenza 351 Future prospects of DNA vaccines for avian influenza 352 Human trial of a DNA vaccine for avian influenza 353 Companies developing genetic vaccines for infections other than AIDS 353 9. Research, Development and Future

Gene Therapy - technologies, markets and companies (From Issuu)

Page 17/19

Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Â&#x192; Â&#x192;

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Gene Therapy - technologies, markets and companies

Product Formats Please select the product formats and the quantity you require.

Digital Copy--USD 5 000.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mrs

Miss

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Gene Therapy - technologies, markets and companies (From Issuu)

Page 18/19

Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

Gene Therapy - technologies, markets and companies (From Issuu)

Page 19/19